Pharmacovigilance – News and Features

NCI scientists have discovered an antibody that neutralizes two highly infectious viruses classified as henipaviruses.

Scientists at The Wistar Institute have collaborated on a major advance in understanding a gene regulator that contributes to some of the deadliest cancers in humans.

Researchers report that the patients with CLL who were treated with a gene therapy protocol began making antibodies that reacted against their own leukemia cells.

Marshfield Clinic has announced an article published in Blood Online entitled “CYP4F2 genetic variant alters required warfarin dose.”

Both companies initiate a three year research collaboration with the purpose to discover and develop selective glucocorticoid receptor.

Revolutionary new ways to tackle certain diseases could be provided by creating drugs which change the bugs in people's guts.

TransTech has acquired all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders.

The results of Phase 1 trial demonstrate that Vyteris’ transdermal technology successfully delivered a peptide molecule in humans without the use of needles.

Findings encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.

The companies have received approval from the regulatory authorities in Denmark to initiate a Phase I clinical trial of the novel anti-cancer agent.